Video

Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder Cancer

Author(s):

Daniel P. Petrylak, MD

In Partnership With:

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with bladder cancer.

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with bladder cancer.

Related Videos
Gustavo Werutsky, MD, PhD, medical oncologist, Breast Cancer Program, Hospital Moinhos de Vento; investigator, Oncology Research Centre, Hospital São Lucas PUCRS University
Ewa Kalinka, MD, PhD
Rohan Garje, MD
Aparna Parikh, MD, medical oncologist, Massachusetts General Hospital
Tycel J. Phillips, MD, MPH
Dr Baljevic on Selinexor Plus Pomalidomide/Dexamethasone in R/R Myeloma
Dr Al Malki on the Potential Use of TSC-100 and TSC-101 After Transplant in AML, ALL, and MDS
Naval G. Daver, MD,
Ami Umesh Badami, MD, medical oncologist, Endeavor Health Medical Group
Phillip Phillip, MD
Related Content
Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.
January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Yousef Zakharia, MD, medical oncologist, vice chair, Genitourinary Malignancy Disease Group, Mayo Clinic Comprehensive Cancer Center; medical director, Experimental Therapeutics Clinic, Mayo Clinic
January 15th 2025

Phase 3 RCC Data Reinforce Efficacy of Standard IO/TKI Doublets Across IMDC Risk Groups

Francine Foss, MD, professor, medicine (hematology) and dermatology, director, Multidisciplinary T Cell Lymphoma Program, Yale School of Medicine; scientific leader, Lymphoma CRT, Yale Cancer Center
October 17th 2024

FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

NGS-Based xT CDx Available in the United States | © Siarhei- stock.adobe.com.
January 15th 2025

NGS-Based xT CDx Test Is Now Commercially Available in United States for Solid Tumor Profiling

Ian Krop, MD, PhD, director, Clinical Trials Office, chief clinical research officer, associate director, clinical sciences, Yale Cancer Center; professor, internal medicine (medical oncology), Yale School of Medicine
January 14th 2025

Emerging HER2-Directed Agents May Address Resistance to SOC Regimens in Pretreated HER2+ Breast Cancer